This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis (NVS) Announces Positive Data on Heart Failure Drug
by Zacks Equity Research
Novartis AG (NVS) recently announced results of a new post-hoc analysis from the PARADIGM-HF study on heart failure drug Entresto.
AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal
by Zacks Equity Research
London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for investigational drug ZS-9.
Why Biotech Stock Gilead (GILD) Could Be a Value Trap
by Arpita Dutt
Gilead's (GILD) valuation looks compelling but is the company really poised for
Glaxo Files for Label Expansion of Influenza Vaccine in US
by Kinjel Shah
GlaxoSmithKline plc (GSK) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA seeking approval to expand the label of Fluarix Quadrivalent ??? an influenza vaccine - for infants six months or older.
Merck's (MRK) Keytruda Gets FDA Nod for Lymphoma Indication
by Zacks Equity Research
Merck & Co., Inc (MRK) announced that it has received FDA approval for Keytruda for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or who had relapsed after three or more prior lines of therapy.
The Zacks Analyst Blog Highlights: Intel, Glaxo, Schwab, Travelers and American Airlines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intel, Glaxo, Schwab, Travelers and American Airlines
Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy
by Zacks Equity Research
Novartis AG (NVS) announced that the FDA has approved Kisqali, for use in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with hormone receptor positive, HR+/HER2- advanced or metastatic breast cancer.
Alexion's sBLA for Soliris Receives FDA Acknowledgement
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) announced that the FDA, on Mar 9, has accepted the supplemental Biologics License Application (sBLA) to expand the indication for Soliris
Epizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus
by Zacks Equity Research
Epizyme, Inc. (EPZM) reported a loss of 60 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of 64 cents.
Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Agenus Inc. (AGEN) reported fourth-quarter 2016 loss of 30 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 33 cents but wider than the year-ago loss of 18 cents.
Valeant (VRX) Issues Notes, Restructures Debt; Shares Down
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc. (VRX) commenced an offer to purchase cash up to $600 million of aggregate principal amount due 2018.
Aerie (AERI) Q4 Loss Widens, Rhopressa NDA Resubmitted
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) posted fourth-quarter 2016 loss of 87 cents per share (including stock-based compensation), wider than both the Zacks Consensus Estimate of a loss of 65 cents
Novartis (NVS) Reports Positive Data on Biosimilar Humira
by Zacks Equity Research
Novartis AG (NVS) announced encouraging data for its proposed biosimilar verison of AbbVie's (ABBV) Humira.
GlaxoSmithKline's Nucala Positive in Label Expansion Study
by Zacks Equity Research
GlaxoSmithKline plc. (GSK) announced that a phase IIIb study evaluating its respiratory drug Nucala (mepolizumab) met all its primary and secondary endpoints.
Impax (IPXL) Q4 Earnings in Line, Revenues Miss Estimates
by Zacks Equity Research
Impax Laboratories Inc. (IPXL) posted fourth-quarter 2016 adjusted earnings of 16 cents per share, in line with the Zacks Consensus Estimate.
Keryx (KERX) Q4 Loss Wider than Expected, Revenues Beat
by Zacks Equity Research
Keryx Biopharmaceuticals Inc. (KERX) reported fourth-quarter 2016 loss of 32 cents per share, narrower than the year-ago loss of 36 cents. However, the loss was wider than the Zacks Consensus Estimate of a loss of 27 cents per share.
Mylan (MYL) Beats on Q4 Earnings, Stock Up on Strong View
by Zacks Equity Research
Shares of Mylan N.V.'s (MYL) were up 7.2% after the company beat expectations in the fourth-quarter 2016 and provided a strong outlook for 2017 amid challenging conditions.
Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis
by Zacks Equity Research
Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis
Valeant (VRX) Tops Q4 Earnings, Shares Down on Tepid View
by Zacks Equity Research
Valeant's (VRX) fourth-quarter results beat expectations but the guidance of 2017 was disappointing.
Endo (ENDP) Beats on Q4 Earnings, Revenues; Guides Low
by Zacks Equity Research
Endo's (ENDP) Q4 results beat expectations but the outlook for 2017 was disappointing and lagged expectations
by Zacks Equity Research
Pharma Industry Outlook - February/March 2017
by Arpita Dutt
The sector is showing signs of recovery with the NYSE ARCA Pharmaceutical Index gaining 5.1% while the NASDAQ Biotechnology Index is up 7.3%.
Intercept (ICPT) Q4 Loss Wider than Expected, Revenues Beat
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $4.84 per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of a loss of $3.58.
Radius Health (RDUS) Posts Wider Loss in Q4
by Zacks Equity Research
Radius Health, Inc. (RDUS) posted a loss of $1.22 per share in the fourth quarter of 2016, compared with a loss of 77 cents per share in the year-ago quarter and wider than the Zacks Consensus Estimate loss of $1.16.
Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line
by Zacks Equity Research
Bayer AG's (BAYRY) fourth-quarter 2016 core earnings increased 10.2% year over year to ???1.19 per share (approximately $1.28). Reported earnings missed the Zacks Consensus Estimate of $1.37.